Derivation of NEM2 affected human embryonic stem cell line Genea078  by Dumevska, Biljana et al.
Stem Cell Research 16 (2016) 427–429
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrLab Resource: Stem Cell LineDerivation of NEM2 affected human embryonic stem cell line Genea078Biljana Dumevska ⁎, Heather Main, Robert McKernan, Divya Goel, Uli Schmidt
Genea Biocells, Sydney, AustraliaIn
P
C
D
O
T
Su
K
A
Li
In
E
K
Se
⁎ Corresponding author.
E-mail address: biljana.dumevska@genea.com (B. Dum
http://dx.doi.org/10.1016/j.scr.2016.02.004
1873-5061/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 26 January 2016
Accepted 1 February 2016
Available online 3 February 2016The Genea078 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying compound heterozygousmutations in the NEB gene, exon 55 deletion & c.15110dupA, indic-
ative of NemalineMyopathy Type 2 (NEM2). Following ICM outgrowth on inactivated human feeders, karyotype
was conﬁrmed as 46, XX and STR analysis demonstrated a female Allele pattern. The hESC line had pluripotent
cell morphology, 76% of cells expressed Nanog, 93% Oct4, 67% Tra1–60 and 97% SSEA4 and gave a Pluritest
Pluripotency score of 42.18, Novelty of 1.37. The cell linewasnegative forMycoplasma and visible contamination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(Resource tablePName of stem cell lineDGenea078 — NEM2 affected (Alternate ID:
SIVF078)stitution Genea Biocells
Sterson who created resource Biljana Dumevskaontact person and email biljana.dumevska@geneabiocells.com
Siate archived/stock date September 2011rigin Human embryos
ype of resource Derived human embryonic stem cell line
b-type NEM2 affected human pluripotent cell line
ey marker expression Nanog, Oct4, Tra1–60, and SSEA4
uthentication Identity and purity of cell line conﬁrmed (Fig.
1 and Tables 1–2 below)
nk to related literature (direct
URL links and full references)
formation in public databases National Institutes of Health registered, NIH:
NIHhESC-14-0252
UK Stem Cell Bank registered, UKSCB:
SCSC14–50thical approval Obtained from the Genea Ethics Committee
on 13 September 2005 under the Australian
National Health and Medical Research Council
(NHMRC) licence 309710Resource detailsDate of derivation August 2011aryotype 46, XX
x Femaleevska).
. This is an open access article under thcontinued)Date of derivatione CC BY-NC-ND liceAugust 2011luripotent YES— by Nanog, Oct4, Tra1–60, and SSEA4 staining and Pluritest
isease status Compound heterozygous exon 55 deletion & c.15110dupA in NEB
gene— Nemaline Myopathy 2 (NEM2) affected, OMIM: 256030
erility The cell line is tested and found negative for Mycoplasma and
any visible contamination.
bling lines
availableYES— Genea079 (XY, NEM2 affected — NIH: NIHhESC-14-0253)
Genea080 (XY, NEM2 affected — NIH: NIHhESC-14-0254)Materials and methods
Cell line derivation
Thehuman embryowas thawed and platedwhole ontomitomycin C
inactivated human feeders (Detroit 551HFF— 90,000/well in 4-well) in
20% Knock out serum in standard hESC culture medium (Amit et al.,
2000)with 20 ng/mL Fgf2. CGH karyotyping and STRproﬁlingwere per-
formed at the ﬁrst cryobanking step from ICM outgrowths maintained
on feeders. Cells were then enzymatically passaged as single cells in
M2 pluripotent cell maintenance medium (Genea Biocells) and CGH/
karyotyping repeated, immunoﬂuorescent pluripotent marker staining,
pluritest and sterility testing performed.
Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 12 (10 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and
duplications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner Cnse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea078 (passage 12, 2 enzymatic) reporting a female cell line
and no abnormalities detected.
CGH summary
Sample name Genea078p12_2
Date reported 10th December 2013
Hybridisation
balance
Balanced hybridization was observed for all chromosomes,
relative to reference DNA.
Copy number change A gain of approximately 629 kb was seen at 7q21.2.
Interpretation Female cell line — no abnormalities detected
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ware (Agilent Technologies).
2. DNA Proﬁling: Passage 3; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288.
Pluripotency assessment
1. Immunoﬂuorescence: Passage 12 (10 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1–60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 12 (10 on feeders, 2 enzymatic); RNAwas collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).Table 2
STR proﬁle; Genea078 (passage 3) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317
SIVF078_p3 11,13 28,30 8,10 10,11 15 6 11
Fig. 1.Pluripotency validation ofGenea078. A) Immunoﬂuorescent staining (10×)of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTest pluripotency (leSterility testing
1. Mycoplasma: Passage 12 (10 on feeders, 2 enzymatic); testing was
performed as per manufacturer's instructions using the MycoAlert
Mycoplasma Detection Kit from LONZA.
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed
consent form can be provided upon request). Donors have received no
payment or ﬁnancial beneﬁts for their donation. Genea078 has been de-
rived from a donated, fully commercially consented embryo, originally
created by assisted reproduction technology (ART) for the purpose
of procreation. The embryo was identiﬁed through pre-implantation
genetic diagnosis to be affected by a genetic mutation and was
declared excess to reproductive needs. Derivation was performed
under Australian National Health and Medical Research Council
(NHMRC) licence 309710. This licence was issued to GENEA on 7 May
2007. More information about the licence can be obtained from theD16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
12 17,24 14,15 16,17 8 12,13 12,13 22,23
t cellmarkers SSEA4 (green),Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 12, 2
ft) and novelty (right) scores with Genea078 (passage 12, 2 enzymatic) outlined in black.
429B. Dumevska et al. / Stem Cell Research 16 (2016) 427–429NHMRC webpage at http://www.nhmrc.gov.au/health-ethics/human-
embryos-and-cloning/database-licences-authorising-use-excess-art-
embryos.
PGD analysis conclusion
Mutation; Compound heterozygous exon 55 deletion & c.15110dupA
in NEB gene. Family tree; both parents are carriers. NemalineMyopathy 2
(NEM2) affected.
Morphology
The derived stem cell line, Genea078, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli.
Genetic analysis
The cell line has been karyotype tested by CGH (Table 1, Supplemen-
tary Fig. 1),which demonstrated 46, XXkaryotype, consistentwith orig-
inal derivation and pre-implantation genetic diagnosis (PGD). Analysis
of STR markers showed Allele pattern consistent with female genotype
(Table 2, Supplementary Fig. 2).
Pluripotency
GENEA078 is pluripotent by;1. Immunoﬂuorescence with 76% Nanog positive, 93% Oct4 positive,
67% Tra1–60 positive and 97% SSEA4 positive (Fig. 1A, quantiﬁed
in 1B).
2. Pluritest with a Pluripotency score of 42.18 and Novelty score of 1.37
(Fig. 1C).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.004.
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